Dr. Wagner is the Vice President of Biology and has served as the head of biology since our inception in 2015. She has more than 20 years of drug discovery experience focused exclusively on metabolic disease targets. Previously, Dr. Wagner served as a Research Fellow at Regulus Therapeutics leading the development of an anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes under a strategic alliance with AstraZeneca. From 2000 to 2013, Dr. Wagner was a research scientist at Arena Pharmaceuticals, Exelixis and X-Ceptor therapeutics, focusing on GPCRs and nuclear receptors in metabolic disease. Dr. Wagner received her Ph.D. at Duke University and was a post-doctoral fellow at the Salk Institute and the Joslin Diabetes Center.
- Our Company▼